We describe a patient with moderately severe (British Thorax Society Step IV/V) asthma requiring regular inhaled and oral corticosteroids to control symptoms who experienced resolution of her asthma following high-dose chemotherapy and autologous stem cell transplantation for breast cancer. As far as the authors are aware this is the first reported case.
A 54-year-old woman was referred with a 1-year history of cough and wheeze. She was a nonsmoker with a family history of asthma. Clinical examination was unremarkable. Skin-prick tests were negative and chest radiograph was normal. Lung function tests supported a diagnosis of lateonset asthma (Table 1) .
She was treated with terbutaline 500 mg four times a day and budesonide 400 mg twice a day, but required intermittent oral steroids for symptom control. Over the next 5 years, she required oral prednisolone approximately every 2-3 months and was hospitalised once with an acute exacerbation but did not require ventilation. Maximal recorded lung function during this period revealed a PEFR of 500 l/min and FEV 1 of 3.0 l.
At the age of 60 years, she presented with a left-sided breast carcinoma. She underwent a wide local excision and axillary dissection. She was entered into the high-dose therapy trial with peripheral blood stem-cell support in primary breast cancer (International Collaborative Cancer Group). Induction chemotherapy with three cycles of 5-fluorouracil (600 mg/m ) and thiotepa (500 mg/m 2 ) followed by reinfusion of stem cells. Subsequently, she received radiotherapy to the tumour bed and was commenced on Tamoxifen.
Following her high-dose chemotherapy and stem cell rescue, her asthmatic symptoms gradually improved and 14 months later she was entirely asymptomatic and was able to stop all her antiasthma medication (Table 1) . CD4 counts are not routinely measured with adjuvant chemotherapy regimen for breast cancer and were not as part of the highdose clinical trial protocol and therefore are not available. When last seen in September 2002, 76 months post highdose chemotherapy and autologous stem-cell transplantation, she remained free of her asthmatic symptoms with no evidence of recurrent breast cancer.
Discussion
There have been many reports in the literature of children whose asthma has resolved while receiving chemotherapy for malignancy, but in most cases the symptoms recurred after the completion of chemotherapy.
2 This is the first report in the literature of complete resolution of late-onset asthma following high-dose chemotherapy and autologous 3 The mechanisms for resolution of this patient's asthmatic symptoms and normalisation of her respiratory function post treatment are not entirely clear. Although this may be an effect on bone marrow eosinophil progenitors, 4 we suggest that it may also be related to the effect of high-dose chemotherapy on T-helper 2-lymphocyte-driven airways inflammation, which is known to be important in the pathogenesis of asthma. 5 Immunosuppressants such as methotrexate have been used in the past in the treatment of asthma but with only modest results. A meta-analysis of 12 trials revealed that methotrexate did allow a small reduction in oral corticosteroid dose, but this was associated with significantly more complications. 6 More recently the role of keliximab, a monoclonal antibody directed against the CD4 molecule has been assessed in 22 patients with severe corticosteroiddependent asthma. 7 Lung function using peak expiratory flow rate was significantly improved in the group receiving the higher dose, 3.0 mg/kg, of keliximab. Thus, therapy aimed at the CD4 þ T cell may be a useful adjunctive therapy in corticosteroid-dependent asthmatics.
Several studies have shown that after high-dose chemotherapy there is a delay in CD4 þ cell recovery. One study showed that in 25 breast cancer patients, dose-intense chemotherapy resulted in a greater than 60% reduction in total CD4 þ T cells and that the recovery was protracted, that is, achieving less than 50% of pre treatment levels after 12-14 months. 8 Another recent study looked at 28 patients who had received the Antman regimen of high-dose chemotherapy for breast cancer. Prior to high-dose chemotherapy all patients had a normal CD4/CD8 ratio, defined as X1. Following autologous transplantation, the vast majority of patients experienced an inversion of this ratio with only 50% demonstrating a normal ratio at 9 months post transplant. Neither the mean nor the median CD4/CD8 had recovered to the pre treatment level after 1 year. 9 High-dose chemotherapy with autologous stem cell rescue has already been used with some success to treat patients with systemic lupus erythematous (SLE), a disease associated with T-lymphocyte abnormalities. 10 In these patients, measurement of immunological parameters had shown that prior to transplantation the T-cell population was skewed towards a T-helper two profile with an increase in interleukin 4 production, but post transplant all serological parameters had normalised and T-cell repertoire diversity and responsiveness was restored.
In conclusion, in light of the recent trial using autologous haematopoietic stem-cell transplantation in the treatment of SLE, our knowledge of the importance of T-helper cells in the pathogenesis of asthma and the effect of chemotherapy on these cells, we hypothesise a novel potential mechanism for the resolution of this patient's asthma. We suggest that the process of high-dose chemotherapy has resulted in a reconstitution of her immune system with a resulting normalisation of her T-cell repertoire and thus resolution of her asthma.
